TABLE 1.
Sensitivity and specificity of CPO detection (the positive/negative testing phase of the study)
| Evaluation criterion | Carbapenemase producer type or status | No. tested | % correct results (95% confidence interval) |
||
|---|---|---|---|---|---|
| BD Phoenix CPO Detect | Rapidec Carba NP interpretationa |
||||
| 1 | 2 | ||||
| Sensitivity | Class A | 110 | 97.3 | 100 | 98.2 |
| Class B | 91 | 95.6 | 98.9 | 98.9 | |
| Class D | 35 | 100 | 94.3 | 94.3 | |
| Dual carbapenemase | 7 | All positiveb | All positiveb | All positiveb | |
| All CPOs | 243 | 97.1 (94.1–98.6) | 98.8 (96.4–99.6) | 97.1 (94.1–98.6) | |
| Specificity | All non-CPOs | 51 | 68.6 (54.9–79.7) | 60.8 (47.1–73.0) | 78.4 (65.4–87.5) |
a
Interpretation 1, borderline results interpreted as positive; interpretation 2, borderline results interpreted as negative.
b
All 7 dual carbapenemase producers yielded a positive result.